Inactive Ingredient Search for Approved Drug Products
You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with S
| Quarter | Inactive Ingredient | Route of Administration | Dosage Form | Maximum Potency per unit dose | Maximum Daily Exposure | Status | |
|---|---|---|---|---|---|---|---|
| Q3 2024 | SILICIFIED MICROCRYSTALLINE CELLULOSE (65 .MICRO.M) | ORAL | CAPSULE | 355mg | Correction | ||
| Q3 2024 | SILICIFIED MICROCRYSTALLINE CELLULOSE (65 .MICRO.M) | ORAL | CAPSULE, EXTENDED RELEASE | 440mg | Correction | ||
| Q3 2024 | SILICIFIED MICROCRYSTALLINE CELLULOSE (65 .MICRO.M) | ORAL | TABLET | 1889mg | Correction | ||
| Q3 2024 | SILICIFIED MICROCRYSTALLINE CELLULOSE (65 .MICRO.M) | ORAL | TABLET, EXTENDED RELEASE | 648mg | Correction | ||
| Q3 2024 | SILICIFIED MICROCRYSTALLINE CELLULOSE (125 .MICRO.M) | ORAL | CAPSULE | 283mg | Correction | ||
| Q3 2024 | SILICIFIED MICROCRYSTALLINE CELLULOSE (125 .MICRO.M) | ORAL | TABLET | 1136mg | Correction | ||
| Q3 2024 | SILICIFIED MICROCRYSTALLINE CELLULOSE (125 .MICRO.M) | ORAL | TABLET, EXTENDED RELEASE | 1063mg | Correction | ||
| Q3 2024 | SILICIFIED MICROCRYSTALLINE CELLULOSE (125 .MICRO.M) | SUBLINGUAL | TABLET | 75mg | Correction | ||
| Q3 2024 | SILICIFIED MICROCRYSTALLINE CELLULOSE (65 .MICRO.M) | ORAL | CAPSULE | 355mg | Correction | ||
| Q3 2024 | SILICIFIED MICROCRYSTALLINE CELLULOSE (65 .MICRO.M) | ORAL | TABLET | 1889mg | Correction | ||
| Q3 2024 | SILICIFIED MICROCRYSTALLINE CELLULOSE (65 .MICRO.M) | ORAL | TABLET, EXTENDED RELEASE | 648mg | Correction | ||
| Q3 2024 | SILICIFIED MICROCRYSTALLINE CELLULOSE (65 .MICRO.M) | ORAL | TABLET, FILM COATED | 100mg | Correction | ||
| Q3 2024 | SILICIFIED MICROCRYSTALLINE CELLULOSE (125 .MICRO.M) | ORAL | CAPSULE | 283mg | Correction | ||
| Q3 2024 | SILICIFIED MICROCRYSTALLINE CELLULOSE (125 .MICRO.M) | ORAL | CAPSULE, EXTENDED RELEASE | 18mg | Correction | ||
| Q3 2024 | SILICIFIED MICROCRYSTALLINE CELLULOSE (125 .MICRO.M) | ORAL | TABLET | 1136mg | Correction | ||
| Q3 2024 | SILICIFIED MICROCRYSTALLINE CELLULOSE (125 .MICRO.M) | ORAL | TABLET, CHEWABLE | 28mg | Correction | ||
| Q3 2024 | SILICIFIED MICROCRYSTALLINE CELLULOSE (125 .MICRO.M) | ORAL | TABLET, DELAYED RELEASE | 159mg | Correction | ||
| Q3 2024 | SILICIFIED MICROCRYSTALLINE CELLULOSE (125 .MICRO.M) | ORAL | TABLET, EXTENDED RELEASE | 1063mg | Correction | ||
| Q3 2024 | SILICIFIED MICROCRYSTALLINE CELLULOSE (125 .MICRO.M) | ORAL | TABLET, FILM COATED | 183mg | Correction | ||
| Q3 2024 | SILICIFIED MICROCRYSTALLINE CELLULOSE (125 .MICRO.M) | ORAL | TABLET, ORALLY DISINTEGRATING | 70mg | Correction | ||
| Q3 2024 | SILICIFIED MICROCRYSTALLINE CELLULOSE (125 .MICRO.M, HIGH-DENSITY) | ORAL | CAPSULE | 1600mg | Correction | ||
| Q3 2024 | SILICIFIED MICROCRYSTALLINE CELLULOSE (125 .MICRO.M, HIGH-DENSITY) | ORAL | CAPSULE, DELAYED RELEASE | 304mg | Correction | ||
| Q3 2024 | SILICIFIED MICROCRYSTALLINE CELLULOSE (125 .MICRO.M, HIGH-DENSITY) | ORAL | TABLET | 1168mg | Correction | ||
| Q3 2024 | SILICIFIED MICROCRYSTALLINE CELLULOSE (125 .MICRO.M, HIGH-DENSITY) | ORAL | TABLET, DELAYED RELEASE | 764mg | Correction | ||
| Q3 2024 | SILICIFIED MICROCRYSTALLINE CELLULOSE (125 .MICRO.M, HIGH-DENSITY) | ORAL | TABLET, EXTENDED RELEASE | 1029mg | Correction | ||
| Q3 2024 | SILICIFIED MICROCRYSTALLINE CELLULOSE (125 .MICRO.M, HIGH-DENSITY) | ORAL | TABLET, FILM COATED | 376mg | Correction | ||
| Q3 2024 | SILICIFIED MICROCRYSTALLINE CELLULOSE (125 .MICRO.M, HIGH-DENSITY) | ORAL | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE | 226mg | Correction | ||
| Q2 2024 | SODIUM HYDROXIDE | OPHTHALMIC | SOLUTION/ DROPS | 0.59 %w/v | Correction | ||
| Q3 2024 | SODIUM HYDROXIDE | OPHTHALMIC | SOLUTION/ DROPS | 0.10 %w/v | Correction | ||
| Q2 2024 | SOYBEAN LECITHIN | ORAL | TABLET | 8mg | Correction | ||
| Q3 2024 | SOYBEAN LECITHIN | ORAL | TABLET | 3mg | Correction | ||
| Q2 2024 | SPEARMINT OIL | ORAL | SYRUP | 0.12 mg/ 5.00 ml | Correction | ||
| Q3 2024 | SPEARMINT OIL | ORAL | SYRUP | NA | Correction | ||
| Q3 2024 | SILICON DIOXIDE | ORAL | CAPSULE, GELATIN COATED | 9.00 mg | 9mg | Deletion | |
| Q3 2024 | SODIUM PHOSPHATE, DIBASIC | NASAL | SPRAY | 0.86 mg | Deletion | ||
| Q3 2024 | SODIUM PHOSPHATE, MONOBASIC | BUCCAL | FILM, SOLUBLE | 0.03 mg | Deletion | ||
| Q3 2024 | SODIUM PHOSPHATE, MONOBASIC | INTRA-ARTICULAR | INJECTION, SUSPENSION | 0.68 %w/v | Deletion | ||
| Q3 2024 | SODIUM PHOSPHATE, MONOBASIC | INTRALESIONAL | INJECTION, SUSPENSION | 0.68 %w/v | Deletion | ||
| Q3 2024 | SODIUM PHOSPHATE, MONOBASIC | INTRAMUSCULAR | INJECTION, POWDER, FOR SOLUTION | 0.18 %w/v | Deletion | ||
| Q3 2024 | SODIUM PHOSPHATE, MONOBASIC | INTRAMUSCULAR | INJECTION, SUSPENSION | 0.68 %w/v | Deletion | ||
| Q3 2024 | SODIUM PHOSPHATE, MONOBASIC | ORAL | SYRUP | 0.50 mg/ 5.00 ml | Deletion | ||
| Q3 2024 | SODIUM PHOSPHATE, MONOBASIC | SOFT TISSUE | INJECTION, SUSPENSION | 0.68 %w/v | Deletion | ||
| Q3 2024 | SODIUM PHOSPHATE, MONOBASIC | TOPICAL | CREAM | 0.30 %w/w | Deletion | ||
| Q3 2024 | SODIUM PHOSPHATE, MONOBASIC | TOPICAL | CREAM, AUGMENTED | 0.20 %w/w | Deletion | ||
| Q3 2024 | SODIUM PHOSPHATE, MONOBASIC | TOPICAL | LOTION | 0.30 %w/w | Deletion | ||
| Q3 2024 | SODIUM PHOSPHATE, MONOBASIC | TOPICAL | LOTION, AUGMENTED | 0.20 %w/w | Deletion | ||
| Q3 2024 | SODIUM STEARYL FUMARATE | ORAL | CAPSULE, GELATIN COATED | 3.00 mg | 3mg | Deletion | |
| Q3 2024 | SODIUM SULFATE ANHYDROUS | TOPICAL | SOLUTION | 0.15 %w/v | Deletion | ||
| Q3 2024 | SUCRALOSE | ORAL | TABLET, EXTENDED RELEASE | 22.00 mg | 44mg | Deletion | |
| Q3 2024 | SULFURIC ACID | TOPICAL | SOLUTION | ADJ PH | Deletion | ||
| Q2 2024 | SODIUM ACETATE | INTRAMUSCULAR | INJECTION | 0.97 %w/v | MDE Replacement | ||
| Q3 2024 | SODIUM ACETATE | INTRAMUSCULAR | INJECTION | 19mg | MDE Replacement | ||
| Q2 2024 | SODIUM CHLORIDE | INTRACAUDAL | INJECTION, SOLUTION | 0.70 %w/v | MDE Replacement | ||
| Q3 2024 | SODIUM CHLORIDE | INTRACAUDAL | INJECTION, SOLUTION | 210mg | MDE Replacement | ||
| Q2 2024 | SODIUM CHLORIDE | INTRAVENOUS | INJECTION, POWDER, FOR SOLUTION | 487.00 mg | MDE Replacement | ||
| Q3 2024 | SODIUM CHLORIDE | INTRAVENOUS | INJECTION, POWDER, FOR SOLUTION | 2922mg | MDE Replacement | ||
| Q2 2024 | SODIUM LAURYL SULFATE | ORAL | POWDER, FOR SUSPENSION | 3.30 mg/ 5.00 ml | MDE Replacement | ||
| Q3 2024 | SODIUM LAURYL SULFATE | ORAL | POWDER, FOR SUSPENSION | 64mg | MDE Replacement | ||
| Q2 2024 | SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE | OPHTHALMIC | SOLUTION/ DROPS | 2.15 %w/v | MDE Replacement | ||
| Q3 2024 | SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE | OPHTHALMIC | SOLUTION/ DROPS | 4mg | MDE Replacement | ||
| Q2 2024 | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | OPHTHALMIC | SOLUTION | 1.27 %w/v | MDE Replacement | ||
| Q3 2024 | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | OPHTHALMIC | SOLUTION | 4mg | MDE Replacement | ||
| Q2 2024 | SODIUM SULFATE ANHYDROUS | OPHTHALMIC | SOLUTION | 0.15 %w/w | MDE Replacement | ||
| Q3 2024 | SODIUM SULFATE ANHYDROUS | OPHTHALMIC | SOLUTION | 7mg | MDE Replacement | ||
| Q2 2024 | SORBIC ACID | TOPICAL | AEROSOL, FOAM | 0.15 %w/w | MDE Replacement | ||
| Q3 2024 | SORBIC ACID | TOPICAL | AEROSOL, FOAM | 6mg | MDE Replacement | ||
| Q2 2024 | SORBITAN TRIOLEATE | ORAL | POWDER, FOR SUSPENSION | 1.50 mg/ 5.00 ml | MDE Replacement | ||
| Q3 2024 | SORBITAN TRIOLEATE | ORAL | POWDER, FOR SUSPENSION | 12mg | MDE Replacement | ||
| Q2 2024 | SORBITOL | OPHTHALMIC | SOLUTION | 6.70 %w/v | MDE Replacement | ||
| Q3 2024 | SORBITOL | OPHTHALMIC | SOLUTION | 2mg | MDE Replacement | ||
| Q2 2024 | SORBITOL SOLUTION | NASAL | SPRAY, METERED | 64.50 mg/ 1.00 ml | MDE Replacement | ||
| Q3 2024 | SORBITOL SOLUTION | NASAL | SPRAY, METERED | 71mg | MDE Replacement |
FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections: IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly
Data Through: July 3, 2024
Database Last Updated: July 31, 2024